You are here

Eli Lilly

Eli Lilly supports Alto Neuroscience in $45m Series C round

Eli Lilly supports Alto Neuroscience in $45m Series C round

Clinical Trials Arena

Alto Neuroscience

psychiatric diesase

Flag link:

The Next Generation of Weight Loss Drugs is Rapidly Approaching

The Next Generation of Weight Loss Drugs is Rapidly Approaching

BioSpace

Flag link:

Manufacturer Lonza says it will not fill obesity drug syringes

Manufacturer Lonza says it will not fill obesity drug syringes

Reuters

drug manufacturing

Flag link:

Why Eli Lilly Stock Flopped While the Market Popped Today

Why Eli Lilly Stock Flopped While the Market Popped Today

Motley Fool

drug manufacturing

Flag link:

Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity

Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity

https://bit.ly/49zNkYL

clinical trials

Flag link:

Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines

Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines

BioSpace

genetic nanomedicine

Flag link:

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

Pharmaphorum

cardiovascular disease

Flag link:

Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started

Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started

Motley Fool

Flag link:

Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.

Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.

Motley Fool

Flag link:

How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets

How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets

Medical Marketing and Media

Flag link:

FDA Approves Eli Lilly’s Zepbound for Chronic Weight Management

FDA Approves Eli Lilly’s Zepbound for Chronic Weight Management

BioSpace

Flag link:

An obesity drug biotech gets buy-in from Eli Lilly, venture firms

An obesity drug biotech gets buy-in from Eli Lilly, venture firms

BioPharma Dive

Flag link:

Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up

Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up

BioSpace

Flag link:

Eli Lilly Just Added Another Potential Billion-Dollar Product

Eli Lilly Just Added Another Potential Billion-Dollar Product

Motley Fool

ulcerative colitis

Flag link:

Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist

Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist

Reuters

Flag link:

Eli Lilly, Redwire head to space to explore next frontier of drug development

Eli Lilly, Redwire head to space to explore next frontier of drug development

Fierce Pharma

drug development

in-space manufacturing

Flag link:

Lilly buys Beam’s option on Verve drug programs

Lilly buys Beam’s option on Verve drug programs

Pharmaforum

Beam Therapeutics

Verve Therapeutics

Flag link:

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Motley Fool

ulcerative colitis

Crohn's Disease

Flag link:

Lilly’s ulcerative colitis therapy mirikizumab finally snags FDA approval

Lilly’s ulcerative colitis therapy mirikizumab finally snags FDA approval

BioSpace

ulcerative colitis

Flag link:

Lilly to help BioAge test muscle regeneration therapy in combo with weight loss drug tirzepatide

Lilly to help BioAge test muscle regeneration therapy in combo with weight loss drug tirzepatide

Fierce Biotech

muscle regeneration

Flag link:

Pages